Vebreltinib Clinical Trials
4 recruitingDrug
Phase 24Phase 12
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
Non-small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University45 enrolled1 locationNCT07655622
Recruiting
Phase 2
Vebreltinib for Advanced or Metastatic CCS
Clear Cell Sarcoma (CCS)
Second Affiliated Hospital, School of Medicine, Zhejiang University30 enrolled1 locationNCT07153887
Recruiting
Phase 2
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Non-small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.120 enrolled1 locationNCT06574347
Recruiting
Phase 1Phase 2
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Non-small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.156 enrolled1 locationNCT06343064